Here's a New Million-Dollar Reason to Buy CRISPR Therapeutics

CRISPR Therapeutics (NASDAQ: CRSP) is heading for an important moment: the potential approval of its first product, exa-cel to treat blood disorders. That's a good reason to buy the stock now and benefit down the road.And this week, the company announced news that adds to the buy case for CRISPR: Big biotech Vertex Pharmaceuticals (NASDAQ: VRTX) has signed a licensing agreement that gives it access to CRISPR's gene editing technology for its type 1 diabetes (T1D) program. The companies aren't strangers to each other. In fact, they're developing exa-cel together.Let's find out why the new agreement is such great news for CRISPR.Continue reading
Weiter zum vollständigen Artikel bei "MotleyFool"